GSK Acquires Syndivia's Prostate Cancer ADC
Despite having its own ADC in development for prostate cancer, GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for £268m.
GSK is doubling down on the modality, fuelling the ongoing industry buzz for the promising anti-tumour modality.
The acquisition combines business intelligence and editorial excellence to reach engaged professionals.
The gold standard of business intelligence.
GSK's move is expected to further develop the treatment for prostate cancer.
Author's summary: GSK buys Syndivia's ADC for prostate cancer.
More News
- Kirby Smart: LSU coaches ‘borrow’ offices, adds context to Brian Kelly firing
- Biofuels and ethanol key to the future of U.S. agriculture - High Plains Journal
- Anthony Edwards has hamstring strain, to be re-evaluated in a week
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Venture Capital, Moonshots, and AI: The 2025 Tech Soap Opera